← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,313	+5	+0.4%	$15.2B
2	2 Charles River Laboratories CRL $14.4B	629	-37	-6%	$10.3B
3	3 DELISTED CATALENT, INC. CTLT	470	+22	+5%	$10.8B
4	4 Sarepta Therapeutics SRPT $1.78B	458	-27	-6%	$10.8B
5	5 CRISPR Therapeutics CRSP $4.86B	416	-33	-7%	$2.81B
6	6 Ultragenyx Pharmaceutical RARE $1.47B	301	+26	+9%	$4.82B
7	7 Intellia Therapeutics NTLA $1.6B	284	-7	-2%	$1.92B
8	8 Krystal Biotech KRYS $9.79B	283	+38	+16%	$5.15B
9	9 Vericel Corp VCEL $2.06B	268	+7	+3%	$2.15B
10	10 BridgeBio Pharma BBIO $12.7B	253	+2	+0.8%	$4.39B
11	11 Legend Biotech LEGN $3.7B	208	+27	+15%	$4.44B
12	12 PTC Therapeutics PTCT $4.98B	203	+4	+2%	$2.93B
13	13 DELISTED BioLife Solutions BLFS	195	+31	+19%	$1.13B
14	14 Rocket Pharmaceuticals RCKT $243M	191	+13	+7%	$1.71B
15	15 DELISTED Arcellx ACLX	186	+19	+11%	$4.13B
16	16 Regenxbio RGNX $454M	186	+5	+3%	$458M
17	17 Fate Therapeutics FATE $232M	164	-18	-10%	$402M
18	18 Allogene Therapeutics ALLO $449M	156	-19	-11%	$460M
19	19 Sana Biotechnology SANA $698M	155	+7	+5%	$639M
20	20 DELISTED bluebird bio BLUE	140	-10	-7%	$32.9M
21	21 4D Molecular Therapeutics FDMT $674M	140	-3	-2%	$630M
22	22 uniQure QURE $1.45B	131	+14	+12%	$193M
23	23 Caribou Biosciences CRBU $49.3M	129	-11	-8%	$103M
24	24 Voyager Therapeutics VYGR $124M	128	+1	+0.8%	$206M
25	25 Precigen PGEN $2.64B	127	-3	-2%	$71.7M